Impact of Visit-to-Visit Variability and Systolic Blood Pressure Control on Subsequent Outcomes in Hypertensive Patients With Coronary Artery Disease (from the HIJ-CREATE Substudy)

Nov 28, 2016 by in CARDIOLOGY Comments Off on Impact of Visit-to-Visit Variability and Systolic Blood Pressure Control on Subsequent Outcomes in Hypertensive Patients With Coronary Artery Disease (from the HIJ-CREATE Substudy)

Although visit-to-visit variability in systolic blood pressure (BP) is a strong predictor of stroke, the impact on subsequent major adverse cardiac events (MACEs) in patients with coronary artery disease (CAD)…

read more

Leukocyte Telomere Length and Coronary Artery Calcium

Nov 28, 2016 by in CARDIOLOGY Comments Off on Leukocyte Telomere Length and Coronary Artery Calcium

Patients with histories of myocardial infarction display shortened leukocyte telomere length (LTL), but conflicting findings have been reported on the relation between LTL and subclinical coronary artery atherosclerosis, as expressed…

read more

Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)

Nov 28, 2016 by in CARDIOLOGY Comments Off on Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)

For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. Also, there are limited data for the predictors of…

read more

Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)

Nov 28, 2016 by in CARDIOLOGY Comments Off on Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)

Establishing the validity of appropriate use criteria (AUC) for percutaneous coronary intervention (PCI) in the setting of stable ischemic heart disease can support their adoption for quality improvement. We conducted…

read more

Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention

Nov 28, 2016 by in CARDIOLOGY Comments Off on Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention

Incomplete revascularization is common after percutaneous coronary intervention (PCI). Whether a “reasonable” degree of incomplete revascularization is associated with a similar favorable long-term prognosis compared with complete revascularization remains unknown….

read more

Reply

Nov 28, 2016 by in CARDIOLOGY Comments Off on Reply

We appreciate your interest in our report detailing the 2014 US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee Meeting regarding Cangrelor, which mirrored the meeting presentations,…

read more
Get Clinical Tree app for offline access